15 Jan SUMAVEL DosePro® Available this Month for Migraine and Cluster Headache
Approved by the FDA in July, SUMAVEL DosePro is being launched this month by Zogenix in partnership with Astellas. The first-of-its-kind needle-free injection system delivers a liquid form of sumatriptan (Imitrex®) directly through the skin (subcutaneously). It is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes in adults.
Medication delivered subcutaneously can be absorbed into the bloodstream quickly, making it a good option for people who want rapid relief for migraine episodes when tablets may not be an option. In studies, SUMAVEL DosePro provided relief from migraine pain within 10 minutes for some people.
The needleless technology enables the medication to be delivered when the devise is pressed to the skin. Compressed nitrogen gas drives a piston through a drug-filled capsule. The drug is expelled under pressure through a hole at the end of the capsule. This creates a thin stream of liquid with just enough pressure to penetrate into the subcutaneous tissue. Delivery occurs within 1/10th of a second. Once used, the empty product is discarded as regular waste.
As with sumatriptan, SUMAVEL DosePro is contraindicated in patients with uncontrolled hypertension, in patients with history, symptoms or signs of ischemic heart disease, coronary artery vasospasm, cerebrovascular or peripheral vascular disease including ischemic bowel disease, and in patients with other significant underlying cardiovascular diseases or known hypersensitivity to sumatriptan.